The most frequently mutated genes, which were found in at least 10% of patients for each indication, were TET2, ASXL1, TP53, FLT3, NPM1, DNMT3A, IDH2, RUNX1 and NRAS in AML; TET2, SF3B1, and ASXL1 in MDS; and JAK2, TET2, and ASXL1 in MPN (S1 Fig). This evidence concerns the gene IDH2 and acute myeloid leukemia.